

Abstract

The invention relates to the utilisation of 5'
5 substituted nucleosides in combination with at least one
cytostatic agent in order to produce a drug for
preventing or reducing the formation of resistance during
cytostatic treatment, and a drug containing BVDU and/or
its metabolites.